vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and CAMDEN NATIONAL CORP (CAC). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $64.3M, roughly 1.3× CAMDEN NATIONAL CORP). CAMDEN NATIONAL CORP runs the higher net margin — 34.0% vs 6.8%, a 27.2% gap on every dollar of revenue.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
BLLN vs CAC — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $64.3M |
| Net Profit | $5.7M | $21.9M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 34.0% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | $1.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $64.3M | ||
| Q4 25 | — | $68.1M | ||
| Q3 25 | $83.5M | $65.4M | ||
| Q2 25 | — | $62.3M | ||
| Q1 25 | — | $60.1M | ||
| Q4 24 | $45.1M | $47.6M | ||
| Q3 24 | $38.4M | $45.0M | ||
| Q2 24 | — | $42.8M |
| Q1 26 | — | $21.9M | ||
| Q4 25 | — | $22.6M | ||
| Q3 25 | $5.7M | $21.2M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | $-11.5M | $14.7M | ||
| Q3 24 | $-14.9M | $13.1M | ||
| Q2 24 | — | $12.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 41.5% | ||
| Q3 25 | 11.5% | 40.5% | ||
| Q2 25 | — | 28.5% | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | 17.0% | 38.7% | ||
| Q3 24 | -32.9% | 35.2% | ||
| Q2 24 | — | 34.7% |
| Q1 26 | — | 34.0% | ||
| Q4 25 | — | 33.1% | ||
| Q3 25 | 6.8% | 32.4% | ||
| Q2 25 | — | 22.6% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | -25.5% | 30.8% | ||
| Q3 24 | -38.8% | 29.1% | ||
| Q2 24 | — | 28.0% |
| Q1 26 | — | $1.29 | ||
| Q4 25 | — | $1.33 | ||
| Q3 25 | $0.10 | $1.25 | ||
| Q2 25 | — | $0.83 | ||
| Q1 25 | — | $0.43 | ||
| Q4 24 | $-1.13 | $1.00 | ||
| Q3 24 | $-1.47 | $0.90 | ||
| Q2 24 | — | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | — |
| Total DebtLower is stronger | $55.0M | $514.4M |
| Stockholders' EquityBook value | $-239.5M | $710.0M |
| Total Assets | $327.5M | $7.0B |
| Debt / EquityLower = less leverage | — | 0.72× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $195.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $191.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $514.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $710.0M | ||
| Q4 25 | — | $696.6M | ||
| Q3 25 | $-239.5M | $676.4M | ||
| Q2 25 | — | $652.1M | ||
| Q1 25 | — | $640.1M | ||
| Q4 24 | $-251.7M | $531.2M | ||
| Q3 24 | $-242.9M | $529.9M | ||
| Q2 24 | — | $508.3M |
| Q1 26 | — | $7.0B | ||
| Q4 25 | — | $7.0B | ||
| Q3 25 | $327.5M | $7.0B | ||
| Q2 25 | — | $6.9B | ||
| Q1 25 | — | $7.0B | ||
| Q4 24 | $302.1M | $5.8B | ||
| Q3 24 | — | $5.7B | ||
| Q2 24 | — | $5.7B |
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $63.9M | ||
| Q3 25 | $13.8M | $36.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $1.0M | ||
| Q4 24 | — | $60.9M | ||
| Q3 24 | — | $-14.5M | ||
| Q2 24 | — | $14.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $58.2M | ||
| Q3 25 | $6.5M | $35.4M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-727.0K | ||
| Q4 24 | — | $55.4M | ||
| Q3 24 | — | $-16.2M | ||
| Q2 24 | — | $13.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 85.5% | ||
| Q3 25 | 7.7% | 54.1% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | -1.2% | ||
| Q4 24 | — | 116.4% | ||
| Q3 24 | — | -36.0% | ||
| Q2 24 | — | 30.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.4% | ||
| Q3 25 | 8.8% | 1.1% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.83× | ||
| Q3 25 | 2.42× | 1.70× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 4.15× | ||
| Q3 24 | — | -1.11× | ||
| Q2 24 | — | 1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
